Back To Schedule
Tuesday, June 20 • 10:30am - 11:00am
#231: A Risk-Based Approach to Quality Management for RWE Studies

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
Component Type: Session

Real World Evidence (RWE) has emerged as an area of great interest and opportunity, especially with ever-increasing capabilities for data mining. RWE has established value in informing prescriber and payer decision-making and interest in RWE generation and use continues to grow with discussions turning to possibilities of its value in supporting new indications and label claims. While broadly the quality objectives of “human research subject protection/patient safety” and “data reliability” apply to RWE, there is no definitive quality regulation or even guidance for the research that generates RWE as there is for interventional, well-controlled clinical trials. In this discussion, we will explore the expectations for quality and compliance in the rapidly expanding RWE ecosystem and how they can be achieved using pragmatic – and perhaps even unconventional – approaches.


David William Fryrear, MSc

avatar for David Fryrear

David Fryrear

Senior Director, R&D Quality Assurance, AbbVie, Inc.
David Fryrear is a Senior Director in R&D Quality Assurance at AbbVie.  In this role, he is the global head of clinical and pharmacovigilance quality assurance and has responsibility for R&D documentation standards and Quality Knowledge Management.  Prior to joining AbbVie in January... Read More →

Tuesday June 20, 2017 10:30am - 11:00am CDT
S400 Concourse McCormick Place 2301 South Martin Luther King Jr. Drive, Gate 4 Chicago, IL 60616